WilmerHale is proud to sponsor the 17th Annual Summit on Biosimilars & Innovator Biologics. Partner Kevin Prussia will speak at the “Biosimilars and Innovator Biologics Year in Review” session addressing the evolving legal, regulatory and commercial landscape impacting biosimilars and next generation biologics. The panel will provide a comprehensive review of the most significant developments from the past year and examine what lies ahead in 2026 and beyond.
Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.
Thank you for your interest in WilmerHale.
